CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.17817478

Available online at: http://www.iajps.com Review Article

NANOTECHNOLOGY USE IN CANCER TREATMENT

[1]Ms. Yogita Devendra Dhole , [2]Ms.Komal D. Rathod

[1]Student, Vardhaman College Of Pharmacy, Koli, Karanja (Lad), Washim

[2]Guide, Assistant Professor, Department Of Quality Assurance Vardhaman College Of Pharmacy, Koli, Karanja (Lad), Maharashtra, India

Abstract:

Cancer remains one of the leading causes of morbidity and mortality worldwide, and limitations of conventional therapies—including poor tumor selectivity, systemic toxicity, multidrug resistance, and inadequate therapeutic index—continue to drive the search for more precise and effective treatment strategies. Nanotechnology has emerged as a transformative platform for cancer management through the development of nanoscale systems engineered for diagnosis, targeted drug delivery, imaging, and combination therapy. Various nanomaterials such as liposomes, polymeric nanoparticles, dendrimers, metal-based structures, and biomimetic vesicles enable the controlled release of therapeutic agents, enhanced circulation time, improved pharmacokinetics, and preferential tumor accumulation through passive and active targeting mechanisms. In addition to drug delivery, nanotechnology has enabled imaging-guided therapy, photothermal and photodynamic interventions, gene and RNA-based treatments, and immune modulation, offering a multifaceted approach to address tumor growth and metastatic progression. Several nano-enabled therapeutics have reached clinical use or advanced clinical investigation, illustrating their translational potential. Despite these advances, challenges remain, including tumor heterogeneity, variable penetration, immune recognition, long-term toxicity, biomaterial clearance, and manufacturing and regulatory complexities that limit widespread clinical adoption. Current efforts focus on the development of intelligent, stimulus-responsive, patient-specific nanosystem; biodegradable and biomimetic carriers; and computationally guided design pipelines to improve safety and therapeutic outcomes. Overall, nanotechnology provides a powerful framework for enhancing precision oncology. Continued interdisciplinary collaboration and innovation are expected to overcome current barriers, enabling next-generation nanotherapeutic platforms with improved efficacy, safety, and clinical accessibility.

Keywords: *Nanotechnology; Cancer therapy; Nanomedicine; Targeted drug delivery; Liposomes; Polymeric nanoparticles; Dendrimers; Biomimetic nanocarriers; Photothermal therapy; Photodynamic therapy; Gene therapy; Immunotherapy; Tumor microenvironment; Clinical translation.*

Corresponding author:

Yogita Devendra Dhole,

Student, Vardhaman College Of Pharmacy,
Koli, Karanja (Lad), Washim

QR CODE

*Please cite this article in press Yogita Devendra Dhole et al., **Nanotechnology Use In Cancer Treatment**, Indo Am. J. P. Sci, 2025; 12(12).*

INTRODUCTION:

Cancer remains one of the leading causes of death globally, with more than 19 million new cases and approximately 10 million deaths reported in 2020 [1]. The growing incidence can be attributed to multiple factors, including aging demographics, genetic predisposition, lifestyle patterns, and environmental exposure. Conventional therapies such as surgery, chemotherapy, and radiotherapy have improved survival rates, but their clinical effectiveness is frequently restricted by systemic toxicity, low specificity, multidrug resistance, and tumor relapse [2]. These limitations highlight the need for innovative approaches that can provide more effective, targeted, and minimally toxic treatment options.

Nanotechnology has emerged as a revolutionary platform capable of addressing many of these constraints. Nanomaterials—typically ranging from 1–100 nm—exhibit unique physicochemical properties, including tunable size, surface charge, and enhanced cellular interactions, enabling improved drug loading and targeted delivery to tumor sites [3]. The field of nanomedicine, which uses nanoscale devices for diagnosis and therapy, has shown great promise in overcoming issues associated with poor solubility, instability, and rapid clearance of traditional chemotherapeutic drugs [4]. One of the fundamental advantages of nanocarriers is their ability to preferentially accumulate in tumor tissues through the enhanced permeability and retention (EPR) effect. Tumors often possess abnormal vasculature characterized by leaky blood vessels and impaired lymphatic drainage, permitting nanoparticles to infiltrate and remain within the tumor microenvironment [5]. In addition to passive targeting mechanisms, nanocarriers can be engineered with surface ligands—such as peptides, antibodies, or aptamers—to actively bind to receptors overexpressed in cancer cells, increasing therapeutic specificity and minimizing off-target toxicity [6].

Beyond targeted durg delivery, nanotechnology enables advanced functional systems for cancer therapy, including controlled drug release, hyperthermia, photothermal therapy (PTT), photodynamic therapy (PDT), gene delivery, and immunomodulation [7]. Stimuli-responsive nanocarriers can release their therapeutic payload in response to internal physiological triggers (e.g., reduced pH, redox gradients, enzymatic activity) or external stimuli (e.g., magnetic fields, heat, light) to improve therapeutic precision[8].

Nanotechnology also plays a significant role in diagnostics (nanodiagnostics) and theranostics. Nanoparticles can serve as contrast agents for MRI, CT, PET, and fluorescence imaging, improving sensitivity and detection of early-stage disease. Theranostic nanoplatforms integrate detection and therapy into a single system, enabling real-time monitoring of treatment response [9].

Despite rapid advancements, clinical translation still faces obstacles. These include variability in the EPR effect among patients and tumor types, rapid clearance by the immune system, potential toxicity of certain nanomaterials, high-cost manufacturing, and regulatory difficulties [10]. Continued refinement of nanoparticle design, enhanced understanding of nano–bio interactions, and advancements in personalized medicine are expected to strengthen the clinical impact of nanotechnology-based therapies. In summary, nanotechnology represents a transformative approach to cancer management, offering precise targeting, improved drug delivery, and multifunctional diagnostic-therapeutic capabilities. With ongoing developments, nanomedicine is poised to play an increasingly integral role in future oncology.



Fig 1.Nanomaterial classes

Types of Nanomaterials in Cancer Treatment

Nanomaterials have profoundly transformed modern oncology due to their nanoscale dimensions, tunable surface properties, multifunctionality, and ability to selectively transport therapeutic and diagnostic payloads to tumor tissues. Their high surface-to-volume ratios, enhanced biocompatibility, and controlled biodegradation allow superior interaction with biological systems compared with conventional drug formulations. Below are the major classes of nanomaterials investigated and used in cancer therapy.

Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers encapsulating hydrophilic or hydrophobic drugs. Their biocompatibility, ability to reduce drug toxicity, and extended blood circulation make them among the earliest clinically validated nanocarriers. PEGylated liposomes inhibit opsonization and prolong systemic retention, enhancing tumor accumulation. Liposomal doxorubicin (Doxil®) significantly decreases cardiotoxicity compared to free doxorubicin, demonstrating therapeutic and safety benefits [11].



Fig 2. Liposomes in Nanotechnology

Polymeric Nanoparticles

Polymeric nanoparticles (PNPs) are fabricated from biodegradable polymers such as PLA, PLGA, and PEG. Their physical structure allows precise drug-release control and protection against premature degradation. Surface functionalization with ligands (peptides, antibodies) facilitates active tumor targeting. PNPs are widely explored for co-delivery of chemotherapeutic agents and genetic material to overcome multidrug resistance (MDR) [12].

Dendrimers

Dendrimers are nanoscale, highly branched, tree-like structures with abundant terminal groups for functionalization. Their interior cavities can encapsulate drugs, while surface groups allow conjugation of targeting ligands. Poly(amidoamine) (PAMAM) dendrimers are frequently used for delivering anticancer drugs, siRNA, and imaging probes. Their monodispersity and tunable architecture make them suitable for theranostic applications [13].

Metallic Nanoparticles

Metallic nanoparticles—especially gold (AuNPs) and silver (AgNPs)—exhibit distinctive physicochemical properties such as enhanced optical absorption, surface plasmon resonance, and high stability. Gold nanoparticles are widely used in photothermal therapy (PTT), wherein absorbed radiation is converted into heat to ablate tumor cells. Metallic nanoparticles can also serve as contrast agents for CT or MRI due to their strong X-ray attenuation characteristics [14].

Magnetic Nanoparticles

Therapeutic iron-oxide nanoparticles (e.g., Fe_3O_4) exhibit superparamagnetic properties, enabling precision imaging and magnetic-guided drug delivery. Under alternating magnetic fields, they generate localized heat for tumor destruction through magnetic hyperthermia. Superparamagnetic iron oxide nanoparticles (SPIONs) are clinically utilized as MRI contrast agents and are exploring expanded roles in drug delivery and theranostics [15].

Carbon-Based Nanomaterials

Carbon-based nanostructures—such as carbon nanotubes (CNTs), graphene oxide (GO), and fullerenes— have unique mechanical strength, electrical conductivity, and high surface areas. CNTs efficiently convert near-infrared (NIR) light to heat, making them ideal for PTT. Graphene-based materials possess large surfaces that allow high drug-loading efficiency and are studied for combined chemo-photothermal therapy [16].



Fig 3. Carbon Dots

Quantum Dots

Quantum dots (QDs) are semiconductor nanocrystals known for strong fluorescence and exceptional photostability. They demonstrate advanced imaging capabilities by providing long-duration, tunable emission signals useful for tumor detection. Although toxicity concerns limit clinical translation, surface modification reduces toxicity and improves clearance properties [17].

Fig. 2 Quantum Dots

Polymeric Micelles

Micelles are amphiphilic nanosystems that self-assemble into core–shell structures. Their hydrophobic core encapsulates insoluble drugs, while the hydrophilic shell enhances systemic stability. Polymeric micelles are especially beneficial for delivering hydrophobic anticancer drugs like paclitaxel and doxorubicin. They exhibit long circulation, improved solubility, and controlled release [18].

Nanogels

Nanogels are three-dimensional, hydrophilic polymer networks capable of absorbing large quantities of water. They demonstrate high loading efficiency, biocompatibility, and stimuli-responsive drug release. Their flexibility improves infiltration into tumor tissue, and their porous structure enables encapsulation of small molecules, proteins, and nucleic acids [19].

Exosomes

Exosomes are endogenous nanovesicles secreted by cells. Since they naturally transport proteins, lipids, and nucleic acids between cells, they serve as promising biomimetic nanocarriers. Their low immunogenicity and inherent biocompatibility enhance their ability to deliver siRNA, miRNA, and chemotherapeutic cargo to tumors [20].

Mesoporous Silica Nanoparticles

Mesoporous silica nanoparticles (MSNs) possess uniform pore structures that enable high drug-loading capacity and customizable release kinetics. Their surface can be functionalized for targeting, and pores can be capped for controlled or stimuli-responsive release. MSNs are being studied extensively for multi- drug delivery, imaging, and phototherapy [21].

Albumin-Based Nanoparticles

Albumin, an abundant natural protein, provides an intrinsically biocompatible platform for nanoparticle construction. Abraxane®, an albumin-bound paclitaxel nanoparticle, is approved for pancreatic, lung, and breast cancer therapy. Albumin nanoparticles exploit receptor-mediated uptake in tumor cells, improving drug transport and distribution with reduced toxicity [22].

Ceramics and Silicate Nanoparticles

Ceramic nanoparticles such as calcium phosphate and silicate derivatives offer robust chemical stability and biocompatibility. Their porous nature allows drug loading, and they can be employed for imaging, radiotherapy enhancement, and gene delivery. Studies are exploring ceramic nanoparticles for dual drug delivery and metal-assisted therapeutic platform [23].

Nanotechnology Therapeutic Approaches

Nanotechnology provides a toolbox of modular strategies that improve cancer therapy by enhancing delivery, increasing selectivity, enabling new modalities (e.g., photothermal ablation), and combining diagnosis with therapy (theranostics). Below I present detailed, original descriptions of the principal nanotechnology-enabled therapeutic approaches, their mechanisms, advantages, and translational status.

Targeted drug delivery (passive and active targeting)

Nanocarriers improve drug pharmacokinetics and biodistribution by protecting payloads from

premature degradation, improving solubility of hydrophobic drugs, and altering circulation half-life. Passive tumour accumulation via the enhanced permeability and retention (EPR) effect remains a primary mechanism: the abnormal tumour vasculature and poor lymphatic drainage allow appropriately sized nanoparticles to extravasate and be retained in the tumour interstitium. However, EPR is heterogeneous between tumour types and patients; consequently, rational nanoparticle design (size, shape, surface chemistry) and "stealth" strategies (e.g., PEGylation) are used to maximize circulation and reduce opsonization. Active targeting augments selectivity by decorating nanoparticle surfaces with ligands (antibodies, peptides, small molecules, aptamers) that bind overexpressed receptors on tumour or stromal cells, improving cellular uptake and intracellular delivery. Precision engineering of nanoparticles (charge, deformability, ligand density) can overcome physiological barriers and enhance tumour penetration. [24].

Stimuli-responsive (smart) delivery systems

Stimuli-responsive nanoparticles are engineered to trigger drug release in response to internal tumour cues (low pH, hypoxia, elevated glutathione, tumour-specific enzymes) or external stimuli (light, heat, ultrasound, magnetic fields). Internal triggers exploit consistent biochemical differences between tumour

and normal tissues: pH-sensitive linkers or coatings shed in acidic endosomes to free cargo, redox-cleavable bonds release drugs in glutathione-rich cytosol, and enzyme-cleavable caps respond to matrix metalloproteinases. Externally triggered systems allow spatiotemporal control — for example light- activated nanoparticles for localized release or magnetic field–activated hyperthermia combined with payload release. These smart systems aim to increase therapeutic index by minimizing off-target exposure and concentrating active drug at the disease site. [25].

Photothermal therapy (PTT) and photodynamic therapy (PDT)

PTT uses nanoparticles (commonly gold nanostructures, carbon nanomaterials, or conjugated polymers) that convert near-infrared (NIR) light into heat, producing localized hyperthermia that kills cancer cells. NIR wavelengths penetrate tissue reasonably well, enabling non-invasive ablation of superficial and some deeper tumours when combined with interstitial light delivery. PDT uses a photosensitizer (PS) that, upon light activation, generates reactive oxygen species (ROS) causing oxidative damage and cell death. Nanoparticles serve multiple roles for both modalities: as photothermal transducers (efficient heat converters), as vehicles to solubilize and protect hydrophobic PSs, and as targeting platforms to concentrate phototherapy agents in tumours. Combining PTT and PDT in a single nanoplatform may produce synergistic tumour destruction while potentially reducing the required light dose. Clinical translation has advanced in preclinical models and early-phase trials for select settings, but clinical challenges include light delivery to deep tumours, controlling heating to avoid normal tissue damage, and ensuring biocompatible clearance of inorganic photothermal agents. [26].

Gene and RNA delivery (siRNA, mRNA, CRISPR cargoes)

Nucleic-acid therapeutics—siRNA, microRNA, mRNA, and gene-editing cargoes—require protection from nucleases and efficient cellular uptake to reach cytosolic or nuclear targets. Lipid nanoparticles (LNPs) and polymeric carriers have become the leading platforms to encapsulate and deliver RNA therapeutics, as evidenced by clinical success in mRNA vaccines and emerging cancer trials. Nanocarriers overcome extracellular and intracellular barriers: they shield nucleic acids during circulation, mediate endosomal escape, and can be surface-modified for tumour tropism. Cancer applications include silencing oncogenes with siRNA, reprogramming tumour cells or immune cells with mRNA, and delivering CRISPR components for targeted genome editing. The field is advancing rapidly, with multiple LNP and nanoparticle RNA formulations in early clinical development for oncology. [27].

Immuno-nanomedicine and vaccine delivery

Nanoparticles can enhance cancer immunotherapy by improving antigen delivery to antigen-presenting cells, co-delivering adjuvants that polarize immune responses, and modulating the tumour immune microenvironment. Nanocarriers facilitate intranodal delivery of antigens and mRNA vaccines, stabilize and present tumour antigens in immunogenic conformations, and enable combination strategies that pair checkpoint inhibitors with localized immunostimulation. Lipid nanoparticles and biodegradable polymeric particles have been engineered to prime cytotoxic T-cell responses and to reprogram suppressive myeloid populations. Recent preclinical and early-phase clinical results indicate that nanoparticle-based cancer vaccines and immunomodulatory nanomedicines can increase antigen-specific T cell responses and, in combination with checkpoint blockade, potentially improve response rates. [28].

Theranostics (integrated diagnostics + therapy)

Theranostic nanoparticles combine imaging and therapeutic functions in a single platform, enabling patient stratification, image-guided therapy, and real-time monitoring of drug delivery and response. Examples include iron-oxide nanoparticles that serve as MRI contrast agents while delivering chemotherapeutics or gold nanoparticles that provide CT contrast while acting as PTT agents.

Theranostics enable clinicians to confirm nanoparticle accumulation prior to therapy, adapt treatment plans dynamically, and measure pharmacodynamics noninvasively. Regulatory and manufacturing challenges remain more complex for theranostic constructs because they combine device-like imaging components with drug action, but the clinical potential for personalized, image-guided oncology is substantial. [29].

Combination and multimodal therapies

Nanoplatforms facilitate co-delivery of multiple agents (e.g., chemotherapy + siRNA, chemo + immunomodulator, chemo + PTT/PDT), enabling synergistic interactions, dose sparing, and coordinated spatiotemporal release. Carefully designed co-delivery systems can overcome adaptive resistance mechanisms (for instance, combining chemotherapeutics with siRNA that silences drug-efflux pumps), sensitize tumours to immunotherapies, or enable sequential therapy (e.g., prime with immunotherapy then deliver cytotoxic drug). Multifunctional nanoparticles that integrate drug cocktails with phototherapy or immune modulators are increasingly examined in preclinical models; translation will require rigorous safety testing and demonstration of additive clinical benefit over standard combinations. [30].

Ultrasound, magnetic and radio-frequency assisted delivery

Physical modalities can be combined with nanoparticles to improve penetration, release, or localized activation. Microbubbles and ultrasound enhance vascular permeability and can transiently open the blood–brain barrier to enable nanoparticle access. Magnetic nanoparticles allow externally guided accumulation and magnetic hyperthermia. Radiofrequency or alternating magnetic fields can activate thermosensitive carriers or induce local heating to promote drug release. These externally actuated strategies offer non-invasive means to increase local concentration and activity of nanomedicines, though they require integration of delivery device considerations into clinical workflows. [31].

Overcoming tumor microenvironment barriers

The tumour microenvironment (TME) — composed of extracellular matrix, stromal cells, abnormal vasculature, hypoxic zones, and immunosuppressive elements — poses major barriers to nanoparticle transport and therapeutic efficacy. Nanotechnology approaches aim to modulate the TME: enzymes or ECM-modifying agents carried by nanoparticles can normalize matrix density, reduce interstitial fluid pressure, or degrade stromal barriers to improve penetration. Other strategies reprogram immunosuppressive cells (e.g., tumor-associated macrophages) toward pro-inflammatory phenotypes using targeted nanodelivery of small molecules or nucleic acids. Effective clinical translation requires patient-specific assessment of TME features and design of nanoparticles tailored to overcome the dominant local barriers. [32].

Safety, clearance and regulatory considerations

While the therapeutic opportunities are compelling, safety, biodistribution, long-term clearance, and manufacturing reproducibility are critical hurdles. Inorganic nanoparticles (some gold, quantum dots) may exhibit long tissue retention unless engineered for biodegradability or excretion; immune recognition and complement activation can limit circulation and cause adverse events. Scalable, GMP-compliant manufacturing and well-defined characterization (size distribution, surface chemistry, endotoxin levels, stability) are required for regulatory approval. Moreover, the heterogeneity of delivery (e.g., variable EPR) implies that patient selection, companion diagnostics, and adaptive dosing strategies will often be necessary. Concerted efforts across materials science, immunology, pharmacology, and regulatory science are essential to bring the next generation of nanotherapeutics safely to patients. [33].

Clinical Applications of Nanotechnology in Cancer Treatment

Nanotechnology has progressed from experimental laboratory research to incorporation into clinical oncology. Several nano-based formulations have been FDA-approved and many more are in clinical trials, primarily improving drug bioavailability, reducing toxicity, maximizing tumour accumulation, and enabling controlled release. Below are key clinical applications.

Liposomal Formulations Pegylated Liposomal Doxorubicin

Doxil® was the first FDA-approved nano-drug and remains widely used in advanced ovarian carcinoma, breast cancer, and Kaposi sarcoma. Encapsulation reduces doxorubicin's cardiotoxicity and enhances tumour delivery. PEGylation increases circulation time and tumour accumulation. Reference: [34]

Liposomal Irinotecan

Approved for metastatic pancreatic cancer in combination with 5-FU + leucovorin. Liposomal packaging improves irinotecan stability and therapeutic exposure. Reference: [35]

Albumin-Bound Nanoparticles Nab-Paclitaxel (Abraxane®)

Albumin-bound paclitaxel enhances drug solubility and tumor uptake via albumin receptor-mediated transport. Approved for breast cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC). Combination with gemcitabine has demonstrated survival benefits in metastatic pancreatic cancer. Reference: [36]

Polymeric Nanoparticles in Clinical Trials

Poly(lactic-co-glycolic acid) (PLGA) and other

biodegradable systems are being explored for sustained drug release and targeted delivery. Some PNPs are designed to co-deliver drugs and nucleic acids to overcome multidrug resistance. Clinical evaluation includes solid tumours such as breast cancer, glioblastoma, and melanoma. Reference: [37]

Nanoparticle-Enabled Radiotherapy Enhancement

Gold nanoparticles (AuNPs) exhibit high X-ray absorption, acting as radiosensitizers. NBTXR3, a hafnium-oxide nanoparticle, has completed trials in soft-tissue sarcoma, demonstrating enhanced local tumour control when combined with radiotherapy.Reference: [38]

Magnetic Nanoparticles for Hyperthermia

Iron oxide nanoparticles (e.g., NanoTherm®) are activated by alternating magnetic fields to generate localized heat capable of killing cancer cells. Used clinically for glioblastoma multiforme (GBM), this approach improves local tumour control when combined with radiotherapy.Reference: [39]

Nanomedicine in Photothermal and Photodynamic Therapy

Several nanocarriers deliver photosensitizers for selectively destroying tumour tissue. Indocyanine green (ICG) nanoparticles improve photothermal efficacy in liver and breast cancers.

Graphene- and gold-based platforms are under evaluation for solid tumours including head-and-neck cancers. Reference: [40]

Nanoparticles for Gene/RNA-Based Cancer Therapy

Lipid nanoparticles (LNPs) have revolutionized nucleic-acid delivery. Cancer-focused RNA nanomedicines include siRNA platforms targeting KRAS, VEGF, and PLK1. Early clinical trials show tumour suppression and immune modulation, particularly in liver and pancreatic cancers.Reference: [41]

Theranostic Nanomedicine

Theranostic systems simultaneously enable imaging and treatment. Iron-oxide nanoparticles provide MRI contrast while delivering drugs.

Gold nanoshells serve as CT contrast while enabling photothermal therapy.

These platforms help clinicians monitor drug distribution, predict response, and adjust treatment.Reference: [42]

Exosome-Based Nanocarriers

Exosomes derived from immune or tumour cells have entered clinical testing because of excellent biocompatibility and immune evasion.Clinical studies use exosomes to deliver siRNA or immune-activating molecules to tumors.

Preliminary results show safety and improved delivery efficiency.Reference: [43]

Clinical Applications in Hematological Cancers

Nanocarriers improve treatment selectivity and reduce toxicity in leukemia, lymphoma, and multiple myeloma.Liposomal vincristine (Marqibo®) is approved for Philadelphia-negative ALL.

Doxil® is used for multiple myeloma when combined with bortezomib.Reference: [44]

Research focuses on biodegradable systems, smart targeting, and imaging-guided delivery to improve future outcomes. Reference: [47]

Challenges & Limitations

Nanotechnology has delivered many promising therapies for cancer, but real-world translation faces multiple technical, biological, regulatory, and societal barriers. Below I list and explain the major challenges in depth.

Biological & physiological barriers

Heterogeneity of the EPR effect. Tumour vasculature varies widely between tumour types, stages and individual patients; the "enhanced permeability and retention" effect that many nanoparticles rely on is therefore inconsistent, limiting predictable accumulation in human tumours. [48]Restricted tumour penetration. Even when nanoparticles extravasate, dense extracellular matrix (ECM), high interstitial fluid pressure, and stromal barriers restrict deep intratumoural transport — large particles may remain near blood vessels and fail to reach hypoxic or invasive tumour cells. [48][49]

Immune recognition and clearance. Opsonization, rapid uptake by the mononuclear phagocyte system (MPS), and complement activation reduce nanoparticle circulation time and can provoke inflammatory responses or hypersensitivity in some patients. Surface "stealth" coatings (e.g., PEG) help but are not a panacea (and PEG-specific antibodies can emerge). [48][50]

Heterogeneous cellular uptake and intracellular trafficking. Different tumour cell subpopulations and stromal cells show variable endocytic pathways; nanoparticles that enter cells may be trapped in endosomes or routed to lysosomes, reducing bioavailability of payloads that require cytosolic or nuclear delivery. [48][51]

Safety, toxicity & long-term fate

Material-dependent toxicity. Some inorganic nanomaterials (gold, quantum dots, certain metal oxides) can accumulate long term in organs (liver, spleen, kidney) if not designed for biodegradation, raising concerns about chronic toxicity and off-target effects. [49][52]

Dose-dependent adverse events and immunotoxicity. High local heating (PTT), ROS generation (PDT), or immune overstimulation (adjuvant-loaded particles) can damage normal tissue or promote systemic side effects if not tightly controlled. [50]

Incomplete clearance and biodegradability. For

regulatory approval, predictable clearance pathways and minimal persistent residues are preferred; designing highly effective nanocarriers that are also rapidly and safely cleared remains a key engineering challenge. [49]

Manufacturing, scale-up & quality control

Reproducible large-scale production. Lab methods (small-batch, manual synthesis) often do not translate directly to GMP-compatible, scalable manufacturing. Critical quality attributes (size distribution, surface chemistry, drug loading) must be tightly controlled between batches. [53]

Analytical characterization. Accurate, standardized assays for nanoparticle identity, purity, aggregation state, endotoxin, and stability are still evolving; regulators demand robust analytical packages that many developers find difficult to assemble. [53]

Regulatory, clinical trial & economic barriers

Complex regulatory classification. Nanomedicines can blur the line between drug, device, and combination product (theranostics), complicating the regulatory pathway, required data, and timelines.

[54] Clinical trial design & endpoints. Demonstrating superiority (or even non-inferiority) to standard therapies is difficult when benefits are incremental (reduced toxicity, improved PK). Selecting meaningful endpoints, companion diagnostics, and stratification biomarkers is essential but not always done early enough. [54][55].

Cost, reimbursement & market adoption. Complex manufacturing and regulatory requirements increase cost; without clear clinical advantages or cost-effectiveness, payers and clinicians may be slow to adopt new nano-therapies. [55]

Translation & scientific reproducibility

Preclinical models not predictive of human outcomes. Many nanoparticle successes in rodents fail in larger animals or humans because of differences in physiology, immune system, tumor microenvironment, and scale. Overreliance on small animal models without translational validation contributes to high attrition.

[48][56]

Intellectual property & standardization. Fragmented IP landscapes and lack of consensus on characterization standards can hamper collaborative development and slow down broad adoption. [53]

Ethical, societal & access issues

Informed consent and long-term monitoring. Unknown long-term effects require careful consent processes and post-marketing surveillance.Global access & equity. Advanced nanomedicines could be expensive; equitable access in low- and middle-income countries will require deliberate policy and pricing strategies.

[55]

Future Perspectives

Despite the challenges above, a convergent set of scientific, technological, and clinical trends point to realistic and high-impact paths forward. Below I outline key directions likely to define the next decade of cancer nanomedicine.

Patient-personalized and precision nanomedicine

Designing nanoparticles guided by patient-specific tumour biology and imaging (to determine EPR status, vascular permeability, and TME composition) will improve selection of patients most likely to benefit. Companion diagnostics and image-guided delivery will be central to personalized nanotherapy. Integration of theranostic platforms that allow "see-then-treat" workflows can accelerate this personalization. [48][54]

Smart, multistage and responsive systems

Next-generation nanocarriers will incorporate dynamic behaviors: size-shifting for deep penetration, charge conversion for cellular uptake, ligand exposure upon arriving in the tumour microenvironment, and multi-stimuli release (pH + enzyme + redox). These multistage systems aim to reconcile contradictory requirements (long circulation vs. deep penetration vs. intracellular delivery). [48][49]

Biomimetic and biodegradable materials

Biomimetic carriers (cell-membrane cloaked nanoparticles, exosome-inspired vesicles) and fully biodegradable inorganic-organic hybrids will reduce immunogenicity and improve clearance. Engineered exosomes and cell-derived vesicles offer natural targeting and immune compatibility, though scalable production remains a challenge. [50][56]

Integration with immunotherapy and gene editing

Nanoparticles are uniquely positioned to deliver combinations: checkpoint inhibitors with local adjuvants, mRNA cancer vaccines to lymph nodes, or CRISPR/Cas components for ex vivo/in vivo gene editing. Combination regimens that reprogram the TME and simultaneously kill cancer cells may produce deeper, more durable responses. [27][28]

AI / computational design and high-throughput screening

Machine learning models and in silico simulations will accelerate formulation optimization (predicting biodistribution, immune interactions, and toxicity), prioritize candidates, and reduce costly trial-and-error in the lab. High-throughput microfluidic manufacturing and screening will help rapidly identify clinically viable formulations. [55][53]

Standardization, regulatory convergence & adaptive trials

Developing harmonized standards for nanoparticle characterization, safety testing, and clinical

endpoints (including validated companion diagnostics) will smooth regulatory pathways. Adaptive trial designs, enriched patient selection, and earlier use of imaging/biomarkers can make trials more efficient and informative. Collaborative consortia (industry, academia, regulators) will be important. [54][53]

Sustainable, scalable manufacturing & cost reduction

Adopting scalable, continuous-flow manufacturing (microfluidics, automated nanoparticle assembly), greener chemistries, and process analytical technologies will reduce batch variability and cost, making nanomedicines more commercially viable and globally accessible. [53][55]

Longitudinal safety studies & real-world evidence

Robust post-marketing surveillance, registries, and real-world evidence collection will clarify long-term safety, inform design improvements, and build clinician/patient confidence for future generations of nanomedicines. [52]

CONCLUSION:

Nanotechnology has transformed the landscape of cancer therapy by enabling the design of highly modular, multifunctional platforms capable of enhancing drug delivery, improving diagnostic precision, and reducing systemic toxicity. Through nanoscale engineering, therapeutic agents can be selectively guided to tumour sites, thereby increasing local therapeutic concentration and minimizing off-target exposure. In addition, advanced nano-formulations—such as liposomes, polymeric nanoparticles, inorganic nanostructures, and biomimetic vesicles—have facilitated controlled release, improved pharmacokinetics, and combinational delivery of chemotherapeutics, immunomodulators, phototherapeutic agents, and gene-based cargos [48–52]. Despite major progress, translation to routine clinical practice remains limited. Barriers include tumour heterogeneity, variable EPR response, inefficient intratumoural penetration, immune recognition, toxicity concerns, long-term biodistribution issues, and manufacturing scale-up challenges [48,49,53]. These constraints highlight the need for more predictive preclinical models, standardized characterization criteria, better targeting strategies, and improved understanding of nanoparticle–biological interactions. Nevertheless, clinically approved nanomedicines such as liposomal doxorubicin, polymer–drug conjugates, and albumin-bound paclitaxel have demonstrated that nanotechnology can provide tangible therapeutic benefits when properly optimized [54]. Ongoing innovations—such as patient-tailored nano-therapeutics, stimuli-responsive and multistage carriers, biodegradable and biomimetic systems, and AI-guided formulation design—promise to enhance safety, targeting accuracy, and treatment response. Integration with immunotherapy, gene editing tools, and image-guided treatment may help overcome tumour resistance and improve therapeutic durability [27,28,55]. With coordinated efforts involving materials science, oncology, regulatory science, and health economics, nanomedicine is expected to transition from selective exploratory applications to broader clinical adoption.{56-57-58}

REFERENCES:

1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2021.
2. Arruebo M, et al. Nanotherapies to overcome cancer drug resistance. Nano Today. 2019.
3. Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Cancer. 2021.
4. Shi J, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017.
5. Fang J, et al. The EPR effect: Unique features of tumor blood vessels for drug delivery. Adv Drug Deliv Rev. 2020.
6. Blanco E, et al. Principles of nanoparticle design for cancer therapy. Nat Biotechnol. 2015.
7. Goel S, et al. Clinical and preclinical applications of nanotechnology-based cancer therapy. Nat Rev Cancer. 2018.
8. Zhang P, et al. Stimuli-responsive nanocarriers for cancer therapy. Mater Sci Eng C. 2021.
9. Chen H, et al. Theranostic nanoparticles for cancer diagnosis and treatment. Adv Mater. 2021.
10. Wilhelm S, et al. Analysis of nanoparticle delivery to tumors. Nat Rev Mater. 2016.
11. Barenholz Y. Doxil®—The first FDA-approved nanodrug. J Control Release. 2012.
12. Jhaveri AM et al. Polymeric nanoparticles for targeted drug delivery. Adv Drug Deliv Rev. 2020.
13. Abbasi E et al. Dendrimers: Fabrication, characterization and applications. J Drug Deliv Sci Technol. 2017.
14. Riley RS et al. Gold nanoparticles in cancer therapy. Nat Rev Cancer. 2019.
15. Hilger I. In vivo applications of magnetic nanoparticles. J Magn Magn Mater. 2017.
16. Chaudhary S et al. Carbon nanotubes in cancer therapy. Cancer Lett. 2022.
17. Li Z et al. Quantum dots for cancer imaging. Acta Pharm Sin B. 2022.
18. Cabral H et al. Micellar nanomedicines in cancer. Nat Rev Clin Oncol. 2018.
19. Oh JK, Lee DI. Nanogels for cancer therapy. Prog Polym Sci. 2018.
20. Kalluri R, LeBleu V. Exosome-mediated tumor

communication. Science. 2020.
21. Manzano M, Vallet-Regí M. Mesoporous silica nanoparticles in cancer. Adv Funct Mater. 2020.
22. Desai N. Albumin-bound paclitaxel. J Clin Oncol. 2009.
23. Hong S et al. Silicate nanoparticles in cancer therapy. Biomaterials. 2021.
24. Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021.
25. Li G, et al. Advances in smart nanotechnology-supported phototherapy and stimuli-responsive systems. Frontiers/PMCID. 2024.
26. Vines JB, et al. Gold nanoparticles for photothermal cancer therapy. Int J Nanomedicine / PMC. 2019.
27. Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021.
28. Han J, et al. Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy. Nanoconvergence. 2023.
29. Yao Y, et al. Nanoparticle-based drug delivery in cancer therapy and imaging (theranostics). Frontiers / PMC. 2020.
30. Overchuk M & Zheng G. Photothermal and photodynamic combination therapies: mechanisms and synergies. ACS Nano. 2023.
31. Paunovska K, et al. Drug delivery systems for RNA therapeutics. Nat Rev Genet/Drug Discov. 2022.
32. Cheng X, et al. Advances in nanomaterial-based targeted drug delivery systems. Pharmaceutics / PMC. 2023.
33. Mitchell MJ, et al. Engineering considerations, nano–bio interactions, and translational barriers. Nat Rev Drug Discov. 2021.
34. Barenholz Y. Doxil® clinical overview. J Control Release.
35. Wang-Gillam A et al. Onivyde in pancreatic cancer. Lancet.
36. Von Hoff D et al. Nab-paclitaxel + gemcitabine for pancreatic cancer. N Engl J Med.
37. Ventola CL. Progress of polymeric nanomedicine. P T Journal.
38. Bonvalot S et al. NBTXR3 radiosensitizer in sarcoma. Lancet Oncol.
39. Maier-Hauff et al. NanoTherm in glioblastoma. J Neurooncol.
40. Zhao X et al. Photothermal nanomedicine advances. Nano Today.
41. Hou X et al. Lipid nanoparticles for RNA therapy. Nat Rev Mater.
42. Janib SM et al. Theranostic nanomedicine. Adv Drug Deliv Rev.
43. EL Andaloussi et al. Exosomes in therapy. Nat Rev Drug Discov.
44. Goldberg SL et al. Marqibo in leukemia. Lancet.
45. Anselmo & Mitragotri. Clinical nanomedicines overview. Bioeng Transl Med.
46. Shi J et al. Cancer nanomedicine. Nat Rev Cancer.
47. Hare J et al. Barriers to nanomedicine translation. Nat Nanotechnol.
48. Gawne P.J., et al. New Opportunities and Old Challenges in the Clinical Translation of Nanotheranostics. Frontiers in Nanomedicine / PMC. 2023.
49. Zhang P., et al. Cancer nanomedicine toward clinical translation. Cell Medicine Review. 2023.
50. Fan D., et al. Nanomedicine in cancer therapy: current strategies and future prospects. Signal Transduction and Targeted Therapy. 2023.
51. Nirmala M.J., et al. Cancer nanomedicine: a review of nano-therapeutics and delivery systems. RSC Advances. 2023.
52. Sell M., et al. Application of Nanoparticles in Cancer Treatment: Toxicity and Clearance Considerations. Nanomaterials (MDPI). 2023.
53. Younis M.A., et al. Clinical translation of nanomedicines: challenges, manufacturing and analytical considerations. Pharmaceutics / Reviews. 2022.
54. Hua S., et al. Current trends and challenges in the clinical translation of nanomedicines. Frontiers in Pharmacology. 2018.
55. Review articles on economic, regulatory and adoption challenges in nanomedicine (summarized from multiple sources: Signal Transduction 2023; Nat Rev Drug Discov 2021; Frontiers 2018).
56. Abdullah K.M., et al. Nanomedicine in Cancer Therapeutics: Current Perspectives. Molecular Cancer. 2025.
57. Gawne P.J., et al. New Opportunities and Old Challenges in the Clinical Translation of Nanotheranostics. 2023.
58. Zhang P., et al. Cancer nanomedicine toward clinical translation. 2023.